What is Aptevo Therapeutics Inc's earnings per share (EPS)?

Aptevo Therapeutics Inc (APVO) reported diluted earnings per share of -$87.27 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aptevo Therapeutics (APVO) Financials

APVO NASDAQ

FY2025 annual

Revenue Not reported for FY2025

Net Income -$26.0M n/m YoY

EPS (Diluted) -$87.27 YoY not available

Operating Cash Flow -$25.6M n/m YoY

Market Cap $2.4M as of Oct 30, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.4x on $6.0M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 30, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the APVO SEC filings page.

This page shows Aptevo Therapeutics Inc (APVO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI APVO FY2025 2026-10-24

Aptevo remains a development-stage business: recurring operating losses are funded mainly through financing rather than operating cash generation.

In FY2025, financing cash inflow was $38.5M versus operating cash outflow of $25.6M, so reported expansion was not financed by the business’s operations. Assets then rose 74.4% while liabilities fell 9.4% from FY2024, pointing to financing that strengthened the balance sheet rather than increased borrowing.

FY2025 R&D spending was $14.5M, above selling and administrative costs of $11.8M; spending remains weighted toward development rather than commercial overhead. The operating loss of $26.3M closely matched operating cash outflow of $25.6M, indicating little accounting-to-cash cushion.

The balance sheet became less liability-heavy: liabilities were 36.1% of assets in FY2025, compared with 69.5% in FY2024. A 3.8x current ratio and the reported liquidity comparison of 10.1 months of annual outflow describe stronger short-term coverage, while the financing inflow explains how that position was rebuilt.

Financial Health Signals

Financial health score not available

Aptevo Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/6

Aptevo Therapeutics Inc passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Aptevo Therapeutics Inc reported a net loss of $26.0M while operations used $25.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$6.4M

YoYn/m

QoQn/m

Aptevo Therapeutics Inc's EBITDA was -$6.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income

-$6.4M

YoYn/m

QoQn/m

Aptevo Therapeutics Inc reported a net loss of $6.4M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

-$5.31

QoQn/m

Aptevo Therapeutics Inc earned -$5.31 per diluted share (EPS) in Q2 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$9.8M

YoY+4.1%

QoQ-32.6%

5Y CAGR-30.5%

10Y CAGR+6.0%

Aptevo Therapeutics Inc held $9.8M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding

QoQ+44.6%

Aptevo Therapeutics Inc had 2M shares outstanding in Q2 2026. Against the prior quarter it is up 44.6%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-105.2%

YoY-10.1pp

QoQ-47.5pp

Aptevo Therapeutics Inc's quarterly ROE was -105.2% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 10.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 47.5 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$3.7M

YoY+11.1%

QoQ-5.8%

Aptevo Therapeutics Inc invested $3.7M in research and development in Q2 2026. This represents an increase of 11.1% from the same quarter a year earlier. Against the prior quarter it is down 5.8%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

APVO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

APVO quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	N/A	N/A	N/A	N/A	$3.1M-74.7%	$12.3M+185.3%	$4.3M-86.7%	$32.4M+40.6%	$23.1M+57.4%	$14.7M+46.8%	$10.0M-70.3%	$33.6M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$19.9M+77.7%	$11.2M+123.8%	$5.0M-59.8%	$12.5M-26.4%	$16.9M
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$12.5M+5.4%	$11.9M+22.9%	$9.6Mn/m	-$2.5M-114.9%	$16.7M
R&D Expenses	N/A	$14.5M+1.1%	$14.4M-16.0%	$17.1M-4.3%	$17.9M-5.9%	$19.0M+6.4%	$17.9M-27.9%	$24.8M-30.0%	$35.4M+21.9%	$29.0M-0.3%	$29.1M-16.1%	$34.7M
SG&A Expenses	N/A	$11.8M+15.1%	$10.2M-13.1%	$11.8M-15.2%	$13.9M-5.6%	$14.7M+5.4%	$14.0M-44.9%	$25.3M-9.9%	$28.1M-18.6%	$34.6M-4.4%	$36.2M-16.0%	$43.0M
Operating Income	N/A	-$26.3Mn/m	-$24.6Mn/m	-$28.9Mn/m	-$28.6Mn/m	-$21.4Mn/m	-$27.5Mn/m	-$41.0Mn/m	-$51.7Mn/m	-$53.9Mn/m	-$138.8Mn/m	-$61.1M
EBITDA	N/A	-$26.1Mn/m	-$24.3Mn/m	-$28.3Mn/m	-$27.7Mn/m	-$20.3Mn/m	-$26.1Mn/m	-$38.7Mn/m	-$49.3Mn/m	-$50.8Mn/m	-$135.4Mn/m	-$58.2M
Income Tax	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$23.3Mn/m	-$19.7Mn/m	-$2.0M
Net Income	N/A	-$26.0Mn/m	-$24.1Mn/m	-$17.4M-316.9%	$8.0Mn/m	-$28.5Mn/m	-$17.8Mn/m	-$40.4Mn/m	-$53.7M-870.0%	$7.0Mn/m	-$112.4Mn/m	-$59.3M
EPS (Basic)	N/A	-$87.27	-$31.46	-$2316.83	$1.57n/m	-$6.07n/m	-$5.23n/m	-$13.86	-$2.39	$0.33n/m	-$5.55n/m	-$2.93
EPS (Diluted)	—	-$87.27	-$31460.23	-$2316.83	$1.57n/m	-$6.07n/m	-$5.23n/m	-$13.86	-$2.39	$0.33n/m	-$5.55n/m	-$2.93
Diluted Shares (Avg)	N/A	315,535	767	7,515	5M+8.9%	5M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$3.7M+11.1%	$3.9M+8.0%	N/A	$4.0M+30.3%	$3.3M-8.6%	$3.6M-3.2%	N/A	$3.1M-20.2%
SG&A Expenses	$2.7M-5.2%	$2.9M+2.3%	N/A	$3.6M+69.0%	$2.9M+21.7%	$2.8M-11.9%	N/A	$2.1M-21.1%
Operating Income	-$6.4Mn/m	-$6.8Mn/m	N/A	-$7.6Mn/m	-$6.2Mn/m	-$6.5Mn/m	N/A	-$5.2Mn/m
EBITDA	-$6.4Mn/m	-$6.8Mn/m	N/A	-$7.6Mn/m	-$6.2Mn/m	-$6.4Mn/m	N/A	-$5.1Mn/m
Net Income	-$6.4Mn/m	-$6.7Mn/m	N/A	-$7.5Mn/m	-$6.2Mn/m	-$6.4Mn/m	N/A	-$5.1Mn/m
EPS (Basic)	-$5.31	-$6.41	N/A	-$2.23	-$151.29	-$1.58	N/A	-$0.36
EPS (Diluted)	-$5.31	-$6.41	N/A	-$2.23	-$151.29	-$1581.81	N/A	-$357.86
Diluted Shares (Avg)	1M	1M	N/A	4M	41,008	4,051	N/A	14,254

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

APVO Balance Sheet

APVO quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$27.2M+74.4%	$15.6M-37.2%	$24.8M-27.4%	$34.2M-39.6%	$56.6M+5.7%	$53.5M+0.3%	$53.4M-20.9%	$67.5M-42.3%	$117.0M+27.4%	$91.9M-28.1%	$127.8M
Current Assets	$23.1M+116.5%	$10.7M-44.1%	$19.1M-30.5%	$27.4M-47.8%	$52.6M+11.2%	$47.3M+57.6%	$30.0M-38.4%	$48.7M-48.8%	$95.1M+33.1%	$71.4M+103.3%	$35.1M
Cash & Equivalents	$21.6M+148.1%	$8.7M-48.5%	$16.9M-25.3%	$22.6M-49.7%	$45.0M+12.7%	$40.0M+221.2%	$12.4M-59.4%	$30.6M+331.8%	$7.1M-26.7%	$9.7M+108.7%	$4.6M
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0-100.0%	$73.7M+64.3%	$44.8Mn/m	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$6.1M+243.9%	$1.8M+73.6%	$1.0M+123.0%	$461K-97.7%	$20.3M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$7.0M+34.5%	$5.2M+143.8%	$2.1M+597.4%	$307K-95.2%	$6.5M
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$29.2M
Total Liabilities	$9.8M-9.4%	$10.8M-14.1%	$12.6M-22.3%	$16.2M-70.7%	$55.4M+49.9%	$37.0M-11.1%	$41.6M+12.1%	$37.1M+6.1%	$35.0M-15.3%	$41.3M+5.5%	$39.1M
Current Liabilities	$6.0M-2.5%	$6.2M-14.1%	$7.2M-17.0%	$8.7M-75.0%	$34.8M+139.1%	$14.5M-62.0%	$38.2M+117.1%	$17.6M-4.9%	$18.5M-5.3%	$19.5M-2.0%	$19.9M
Non-Current Liabilities	$3.8M-18.7%	$4.6M-14.2%	$5.4M-28.4%	$7.5M-63.5%	$20.6M-8.0%	$22.4M+573.7%	$3.3M-82.9%	$19.5M+18.3%	$16.5M-24.3%	$21.7M+13.2%	$19.2M
Long-Term Debt	N/A	N/A	$0-100.0%	$1.5M-60.7%	$3.7M-86.9%	$28.2M	N/A	$19.3M+22.6%	$15.7M-14.4%	$18.4M	N/A
Total Equity	$17.4M+265.5%	$4.8M-61.1%	$12.2M-32.0%	$18.0M+1378.1%	$1.2M-92.7%	$16.6M+40.1%	$11.8M-61.1%	$30.4M-62.9%	$82.0M+62.2%	$50.6M-42.9%	$88.6M
Retained Earnings	-$275.1Mn/m	-$247.6Mn/m	-$223.4Mn/m	-$206.0Mn/m	-$214.1Mn/m	-$185.6Mn/m	-$167.9Mn/m	-$127.4Mn/m	-$73.7Mn/m	-$80.7Mn/m	-$232.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$14.5M-7.1%	$19.9M+138.6%	$27.2M+74.4%	$27.0M+78.2%	$15.6M+4.7%	$8.3M-52.7%	$15.6M-37.2%	$15.1M-44.2%
Current Assets	$10.8M-2.6%	$16.0M+343.1%	$23.1M+116.5%	$22.6M+126.2%	$11.1M+15.7%	$3.6M-70.1%	$10.7M-44.1%	$10.0M-52.6%
Cash & Equivalents	$9.8M+4.1%	$14.5M+579.1%	$21.6M+148.1%	$21.1M+171.6%	$9.4M+16.7%	$2.1M-79.1%	$8.7M-48.5%	$7.8M-59.4%
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Total Liabilities	$8.5M-6.8%	$8.3M-15.5%	$9.8M-9.4%	$9.6M-10.5%	$9.1M-13.0%	$9.8M-14.8%	$10.8M-14.1%	$10.7M-13.6%
Current Liabilities	$5.2M+6.1%	$4.8M-11.7%	$6.0M-2.5%	$5.6M-4.6%	$4.9M-9.7%	$5.4M-14.4%	$6.2M-14.1%	$5.9M-14.0%
Non-Current Liabilities	$3.3M-21.8%	$3.5M-20.2%	$3.8M-18.7%	$4.0M-17.6%	$4.2M-16.5%	$4.4M-15.4%	$4.6M-14.2%	$4.8M-13.1%
Total Equity	$6.0M-7.4%	$11.6Mn/m	$17.4M+265.5%	$17.4M+293.5%	$6.5M+46.2%	-$1.5M-124.1%	$4.8M-61.1%	$4.4M-70.0%
Retained Earnings	-$288.3Mn/m	-$281.9Mn/m	-$275.1Mn/m	-$269.2Mn/m	-$260.2Mn/m	-$254.0Mn/m	-$247.6Mn/m	-$241.3Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

APVO Cash Flow Statement

APVO quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	-$25.3M	-$25.6Mn/m	-$23.8Mn/m	-$11.7Mn/m	-$21.0Mn/m	-$21.7Mn/m	-$29.3Mn/m	-$42.4Mn/m	-$51.4Mn/m	-$41.6Mn/m	-$36.9Mn/m	-$48.8M
Depreciation & Amortization	N/A	$240K-31.8%	$352K-37.9%	$567K-37.1%	$901K-21.2%	$1.1M-18.6%	$1.4M-37.1%	$2.2M-6.5%	$2.4M-23.6%	$3.1M-7.0%	$3.4M+15.7%	$2.9M
Stock-Based Compensation	N/A	$96K-91.0%	$1.1M-51.3%	$2.2M+21.7%	$1.8M+9.7%	$1.6M+30.9%	$1.3M-21.5%	$1.6M-25.3%	$2.1M-56.2%	$4.9M+28.2%	$3.8M+244.1%	$1.1M
Capital Expenditures	N/A	N/A	N/A	N/A	$29K-95.9%	$713K+710.2%	$88K-42.5%	$153K-84.3%	$976K-30.4%	$1.4M-44.2%	$2.5M+64.5%	$1.5M
Free Cash Flow	N/A	N/A	N/A	N/A	-$21.1Mn/m	-$22.4Mn/m	-$29.4Mn/m	-$42.5Mn/m	-$52.4Mn/m	-$43.0Mn/m	-$39.4Mn/m	-$50.3M
Investing Cash Flow	N/A	$0n/m	$0n/m	$0n/m	-$29Kn/m	-$713K-102.5%	$28.0M+584.2%	$4.1M-94.4%	$72.8M+147.1%	$29.5M	N/A	N/A
Financing Cash Flow	$25.7M	$38.5M+146.9%	$15.6M+160.0%	$6.0Mn/m	-$2.6M-110.0%	$26.2M+9.6%	$23.9M+18.5%	$20.1Mn/m	-$787K-104.0%	$19.5M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$5.5Mn/m	-$8.0Mn/m	-$5.2Mn/m	-$6.7Mn/m	-$7.1Mn/m	-$6.6Mn/m	-$5.8Mn/m	-$5.2Mn/m
Depreciation & Amortization	$32K-34.7%	$35K-42.6%	$81K+14.1%	$49K-41.7%	$49K-46.2%	$61K-42.5%	$71K-38.8%	$84K-31.7%
Stock-Based Compensation	N/A	$57K-68.3%	N/A	N/A	N/A	$180K-75.0%	N/A	$149K-67.3%
Investing Cash Flow	$0n/m	$0n/m	N/A	N/A	$0	$0	N/A	N/A
Financing Cash Flow	$726K-94.9%	$871Kn/m	$5.8M-13.8%	$18.3M+273.6%	$14.4M+261.9%	$0n/m	$6.7M+120.6%	$4.9M+13.0%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

APVO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

APVO quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	38.5%-12.8pp	51.4%-14.4pp	65.8%+90.7pp	-24.9%-74.5pp	49.6%
Operating Margin	N/A	N/A	N/A	-919.7%	-174.1%	-638.1%	-126.3%	-224.0%	-368.1%	-1389.8%	-181.8%
Net Margin	N/A	N/A	N/A	257.8%	-231.5%	-411.9%	-124.8%	-232.8%	47.6%	-1125.8%	-176.5%
Return on Equity	-149.4%+358.1pp	-507.5%-365.0pp	-142.5%-187.1pp	44.7%+2384.9pp	-2340.2%-2233.2pp	-107.0%+234.6pp	-341.6%-165.0pp	-176.6%-185.1pp	8.5%+230.8pp	-222.3%-155.4pp	-66.9%
Return on Assets	-95.5%+59.3pp	-154.8%-84.7pp	-70.1%-93.5pp	23.5%+73.7pp	-50.3%-17.1pp	-33.1%+42.6pp	-75.7%+3.8pp	-79.5%-85.5pp	6.0%+128.3pp	-122.4%-76.0pp	-46.4%
Current Ratio	3.81+2.1x	1.72-0.9x	2.64-0.5x	3.15+1.6x	1.51-1.7x	3.25+2.5x	0.78-2.0x	2.76-2.4x	5.14+1.5x	3.65+1.9x	1.76
Debt-to-Equity	N/A	N/A	0.00-0.1x	0.08-3.0x	3.05+1.3x	1.70	N/A	0.63+0.4x	0.19-0.2x	0.36	N/A
Liabilities-to-Equity	0.56-1.7x	2.28+1.2x	1.03+0.1x	0.90-44.6x	45.55+43.3x	2.23-1.3x	3.51+2.3x	1.22+0.8x	0.43-0.4x	0.82+0.4x	0.44
Asset Turnover	N/A	N/A	N/A	0.09-0.1x	0.22+0.1x	0.08-0.5x	0.61+0.3x	0.34+0.2x	0.130.0x	0.11-0.2x	0.26
FCF Margin	N/A	N/A	N/A	-676.0%	-182.2%	-682.4%	-131.2%	-227.2%	-293.2%	-394.3%	-149.7%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-105.2%-10.1pp	-57.7%	N/A	-43.4%+72.0pp	-95.1%+36.7pp	N/A	N/A	-115.4%-72.4pp
Return on Assets	-43.8%-4.1pp	-33.7%+43.2pp	N/A	-28.0%+5.7pp	-39.7%-0.3pp	-76.8%-38.0pp	N/A	-33.7%-10.3pp
Current Ratio	2.08-0.2x	3.36+2.7x	3.81+2.1x	4.03+2.3x	2.27+0.5x	0.67-1.2x	1.72-0.9x	1.70-1.4x
Liabilities-to-Equity	1.400.0x	0.71	0.56-1.7x	0.55-1.9x	1.39-0.9x	N/A	2.28+1.2x	2.43+1.6x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Aptevo Therapeutics Inc APVO	FY2025	N/A	-$26.0M	N/A	$2.4M	—
Xenetic Biosciences, Inc. XBIO	FY2025	$3.0M	-$2.7M	-90.1%	$4.8M	66/100
GRI Bio, Inc. GRI	FY2025	N/A	-$12.0M	N/A	$3.3M	—
Onconetix, Inc. ONCO	FY2025	$815K	-$14.0M	N/A	$3.3M	—
Oragenics Inc. OGEN	FY2025	N/A	-$9.8M	N/A	$1.7M	—
Quoin Pharmaceuticals, Ltd. QNRX	FY2025	N/A	-$15.8M	N/A	$21.8M	—

Where Aptevo Therapeutics Inc Ranks

Frequently Asked Questions

Is Aptevo Therapeutics Inc profitable?

No, Aptevo Therapeutics Inc (APVO) reported a net loss of $26.0M in fiscal year 2025.

What is Aptevo Therapeutics Inc's EBITDA?

Aptevo Therapeutics Inc (APVO) had EBITDA of -$26.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Aptevo Therapeutics Inc's return on equity (ROE)?

Aptevo Therapeutics Inc (APVO) has a return on equity of -149.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Aptevo Therapeutics Inc's operating cash flow?

Aptevo Therapeutics Inc (APVO) recorded an outflow of $25.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Aptevo Therapeutics Inc's total assets?

Aptevo Therapeutics Inc (APVO) had $27.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Aptevo Therapeutics Inc spend on research and development?

Aptevo Therapeutics Inc (APVO) invested $14.5M in research and development during fiscal year 2025.

How many shares does Aptevo Therapeutics Inc have outstanding?

Aptevo Therapeutics Inc (APVO) had 1M shares outstanding as of fiscal year 2025.

What is Aptevo Therapeutics Inc's current ratio?

Aptevo Therapeutics Inc (APVO) had a current ratio of 3.81 as of fiscal year 2025, which is generally considered healthy.

What is Aptevo Therapeutics Inc's liabilities-to-equity ratio?

Aptevo Therapeutics Inc (APVO) had a liabilities-to-equity ratio of 0.56 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

What is Aptevo Therapeutics Inc's return on assets (ROA)?

Aptevo Therapeutics Inc (APVO) had a return on assets of -95.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Aptevo Therapeutics Inc's P/E ratio?

Aptevo Therapeutics Inc (APVO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $2.4M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Aptevo Therapeutics Inc's price-to-sales ratio?

Aptevo Therapeutics Inc (APVO) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.4M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Aptevo Therapeutics Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Aptevo Therapeutics Inc (APVO) held $21.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $25.6M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Aptevo Therapeutics Inc's Piotroski F-Score?

Aptevo Therapeutics Inc (APVO) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aptevo Therapeutics Inc's earnings high quality?

Aptevo Therapeutics Inc (APVO) reported a net loss of $26.0M while operations used $25.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.